This football season, Teva is increasing education around tardive dyskinesia (TD) by launching ‘The Other TD’ campaignTD is a chronic movement disorder impacting one in four people who take certain prescription mental health medications. While TD can impact your daily life, it can be treated without interrupting your mental health treatment1-4Younger individuals, men, and racial and ethnic minority groups have lower rates of formal diagnoses despite the high impact the movements often have on all aspects of ...

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Monday, November 10, 2025, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the third quarter ended September 30, 2025. Webcast InformationDate: Monday, November 10, 202 ...

Financial Performance - Total net product revenue reached $171.0 million, a 63% year-over-year increase[12, 27] - AUVELITY net product sales were $136.1 million, representing a 69% year-over-year growth[12, 27, 46] - SUNOSI net product revenue amounted to $32.8 million, a 35% year-over-year increase[12, 27, 56] - SYMBRAVO net product sales were $2.1 million[12, 27] - Cash and cash equivalents stood at $325.3 million as of September 30, 2025[12] Pipeline Development & Regulatory Milestones - An sNDA for AXS-05 in Alzheimer's disease agitation has been submitted to the FDA[12, 25, 74] - An NDA submission for AXS-12 for cataplexy in narcolepsy is anticipated in 4Q 2025[12, 25, 109] - A Phase 3 trial of solriamfetol in children and adolescents with ADHD is anticipated in 4Q 2025[12, 25, 82] Strategic Focus & Market Potential - The company is targeting therapeutic areas with high unmet needs, with potential approvals through 2028[11] - The company estimates a combined peak sales potential of >$16 billion across its pipeline[21]

Key Points Novo Nordisk has several catalysts that could jolt its sluggish stock over the next few years. Regeneron is handling biosimilar competition well while mitigating the threat with new launches. 10 stocks we like better than Novo Nordisk › What's better than investing in a stock with a promising outlook? Investing in a beaten-down stock with a promising outlook. Scooping up shares of great companies after they have experienced setbacks but before they make a strong comeback is a great way t ...

Market Overview - November begins with stock futures higher, following a successful October driven by artificial intelligence momentum [1] - The S&P 500 rose 2.3%, Dow Jones Industrial Average increased by 2.5%, and Nasdaq Composite jumped 4.7% in October [4] Berkshire Hathaway - Berkshire Hathaway's cash reserves reached a record high of $381.6 billion, surpassing the previous record of $347.7 billion [2] - The company reported a 34% increase in operating profit to $13.485 billion in Q3, with overall earnings rising 17% year over year to $30.8 billion [3] Big Tech Earnings - Major tech companies, including Meta, Amazon, Alphabet, and Microsoft, reported strong digital advertising sales, indicating resilience in ad budgets despite economic uncertainty [4] - The collective capital expenditure for the four tech giants is expected to exceed $380 billion this year, reflecting ongoing investment in AI [5] SNAP Benefits - A federal judge mandated that the Trump administration must utilize emergency funds to continue SNAP food benefits during the government shutdown, affecting 42 million Americans [6][7] Pharmaceutical Market - Eli Lilly and Novo Nordisk dominate the weight loss and diabetes drug market, which could reach $100 billion by 2030 [10] - Both companies are focusing on increasing supply and convenience while testing new uses for their drugs to fend off competition [11]

Key Points A former pandemic favorite and a lesser-known biopharmaceutical stock both have value to add to a long-term investor's portfolio. Pfizer's growth has slowed from a few years ago, but its tepid stock price is not telling the whole story of this innovative company. Vertex Pharmaceuticals is rapidly expanding its portfolio in the rare-disease drug market, and growing its profits in the process. 10 stocks we like better than Pfizer › The healthcare industry revolves around constant innovat ...

Getty Images Listen below or on the go via Apple Podcasts and Spotify The director for the Center for Drug Evaluation and Research was accused of making false statements about a drug and soliciting a bribe. (0:15) Baidu’s Apollo Go hits driverless ride landmark. (1:20) Trump says only U.S. will get access to Nvidia’s Blackwell line. (2:08) The following is an abridged transcript: George Tidmarsh is out as director of the FDA’s Center for Drug Evaluation and Research amid accusations that he made fal ...

Group 1: FDA and Aurinia Pharmaceuticals - George Tidmarsh has resigned as director of the FDA's Center for Drug Evaluation and Research amid accusations of making false statements about Aurinia Pharmaceuticals' lupus nephritis treatment and soliciting a bribe [4][3] - Aurinia Pharmaceuticals has filed a federal lawsuit against Tidmarsh, claiming he made false statements and sought a bribe in retaliation against its chairman, Kevin Tang [4] - Tidmarsh criticized the FDA's new National Priority Review Voucher program, suggesting it could alter drug approval processes without adequate legal support [4] Group 2: Autonomous Driving - Baidu's Apollo Go unit has achieved a milestone of over 250,000 fully driverless rides per week as of October 31, matching the weekly rides reported by Waymo [5] - The total number of robotaxi rides operated by Apollo Go during the quarter ending June 30 was 2.2 million, averaging around 169,000 rides per week [6] Group 3: Nvidia and U.S. Market - President Trump announced that Nvidia's most advanced Blackwell chips will be exclusively available to U.S. companies, restricting access to other countries [7]

BioNTech raised its sales forecast for the year, helped by a boost from its partnership with Bristol-Myers Squibb https://t.co/0ZVQtxHGor ...

To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com. The archived webcast will be available for 30 days following the call. Accessibility StatementSkip Navigat ...